Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Proc Natl Acad Sci U S A ; 114(21): E4288-E4295, 2017 05 23.
Artículo en Inglés | MEDLINE | ID: mdl-28490495

RESUMEN

Alternative splicing changes the CaV1.2 calcium channel electrophysiological property, but the in vivo significance of such altered channel function is lacking. Structure-function studies of heterologously expressed CaV1.2 channels could not recapitulate channel function in the native milieu of the cardiomyocyte. To address this gap in knowledge, we investigated the role of alternative exon 33 of the CaV1.2 calcium channel in heart function. Exclusion of exon 33 in CaV1.2 channels has been reported to shift the activation potential -10.4 mV to the hyperpolarized direction, and increased expression of CaV1.2Δ33 channels was observed in rat myocardial infarcted hearts. However, how a change in CaV1.2 channel electrophysiological property, due to alternative splicing, might affect cardiac function in vivo is unknown. To address these questions, we generated mCacna1c exon 33-/--null mice. These mice contained CaV1.2Δ33 channels with a gain-of-function that included conduction of larger currents that reflects a shift in voltage dependence and a modest increase in single-channel open probability. This altered channel property underscored the development of ventricular arrhythmia, which is reflected in significantly more deaths of exon 33-/- mice from ß-adrenergic stimulation. In vivo telemetric recordings also confirmed increased frequencies in premature ventricular contractions, tachycardia, and lengthened QT interval. Taken together, the significant decrease or absence of exon 33-containing CaV1.2 channels is potentially proarrhythmic in the heart. Of clinical relevance, human ischemic and dilated cardiomyopathy hearts showed increased inclusion of exon 33. However, the possible role that inclusion of exon 33 in CaV1.2 channels may play in the pathogenesis of human heart failure remains unclear.


Asunto(s)
Potenciales de Acción/genética , Canales de Calcio Tipo L/genética , Síndrome de QT Prolongado/genética , Taquicardia/genética , Complejos Prematuros Ventriculares/genética , Potenciales de Acción/fisiología , Empalme Alternativo/genética , Animales , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo L/metabolismo , Células Cultivadas , Colforsina/farmacología , Fenómenos Electrofisiológicos/genética , Insuficiencia Cardíaca/genética , Insuficiencia Cardíaca/patología , Isoproterenol/farmacología , Síndrome de QT Prolongado/patología , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Miocardio/metabolismo , Miocitos Cardíacos/metabolismo , Nifedipino/farmacología , Ratas , Eliminación de Secuencia/genética , Taquicardia/patología , Complejos Prematuros Ventriculares/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA